{"id":328633,"date":"2025-10-24T08:11:50","date_gmt":"2025-10-24T08:11:50","guid":{"rendered":"https:\/\/www.europesays.com\/us\/328633\/"},"modified":"2025-10-24T08:11:50","modified_gmt":"2025-10-24T08:11:50","slug":"eli-lilly-novo-nordisk-stock-fall-on-trump-glp-1-price-comments","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/328633\/","title":{"rendered":"Eli Lilly Novo Nordisk stock fall on Trump GLP-1 price comments"},"content":{"rendered":"

\"President<\/p>\n

Shares of Eli Lilly<\/a> and Novo Nordisk<\/a> dropped Friday, after President Donald Trump<\/a> said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of their current list price.<\/p>\n

“In London, you’d buy a certain drug for $130 and even less than that … $88 as of… a month ago. And in New York, you pay $1,300 for the same thing,” Trump said during a Thursday afternoon event about in vitro fertilization at the White House. “Instead of $1,300 you’ll be paying about $150 and they’ll be paying $150 so we’re going to pay the same thing.”<\/p>\n

Asked by a reporter what drug he was referring to, Trump replied, “I was referring to Ozempic or … the fat loss drug.”<\/p>\n

At that point, Centers for Medicare and Medicaid Administrator Dr. Mehmet Oz interjected and stressed that the administration has not yet agreed to GLP-1 price reductions with drugmakers.<\/p>\n

“We have not negotiated those yet … We’re going to be rolling these out over time, the GLP category of drugs, which includes Ozempic have not been negotiated yet,” Oz said.<\/p>\n

Just a week ago, Oz had said that the administration was “in the middle of a lot of action” with price discussions with weight loss drugmakers.<\/p>\n

\"CMS<\/p>\n

Eli Lilly shares closed 2% lower Friday, while Novo Nordisk’s stock fell 3% in U.S. trading. Meanwhile, shares of Hims & Hers Health<\/a> \u2014 which sells much cheaper compounded GLP-1s \u2014 plunged more than 15%.<\/p>\n

Eli Lilly and Novo Nordisk were among 17 of the largest U.S. pharmaceutical companies that received letters<\/a> from the Trump administration following the president’s executive order on so-called most-favored nation pricing, demanding that businesses bring U.S. drug prices in line with those in other developed nations.<\/p>\n

Pfizer<\/a> and AstraZeneca<\/a> have signed on to the president’s initiative, striking drug pricing deals<\/a> with the administration. But Trump and Oz’s comments make it clear the administration is looking to get the weight loss drugmakers on board.<\/p>\n

$150 GLP-1 would be cheaper than compounders<\/p>\n

While demand for weight loss drugs has grown, price has remained an obstacle for consumers and employers.<\/p>\n

Only about one in five large employers currently offer GLP-1s for weight loss, according to a new survey from the Kaiser Family Foundation. Of those who do, two-thirds say the high cost drugs have had a “significant” impact on their prescription drug spending.<\/p>\n

Workers who don’t get coverage through health insurance have increasingly turned to the cash market to buy the drugs on their own.<\/p>\n

Eli Lilly and Novo Nordisk sell discounted versions of their diabetes and weight loss medications on their direct-to-consumer sites at roughly $500 a month. Telehealth providers like Hims & Hers offer compounded versions of GLP-1s for less than half that price, anywhere between $130 to $200 per month.<\/p>\n

If the administration could bring the cash price for popular weight loss drugs like Lilly’s Zepbound and Novo Nordisk’s Wegovy down to $150, that would be competitive with compounded options and could have a major impact on the current cash market.<\/p>\n","protected":false},"excerpt":{"rendered":"Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to…\n","protected":false},"author":3,"featured_media":328634,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[59959,81,77,69,37520,210,9166,62220,1060,29880,7069,15008,9159,67,132,68],"class_list":{"0":"post-328633","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-astrazeneca-plc","9":"tag-business-news","10":"tag-donald-j-trump","11":"tag-donald-trump","12":"tag-eli-lilly-and-co","13":"tag-health","14":"tag-health-care-industry","15":"tag-hims-hers-health-inc","16":"tag-medication","17":"tag-mehmet-oz","18":"tag-novo-nordisk-a-s","19":"tag-pfizer-inc","20":"tag-social-issues","21":"tag-united-states","22":"tag-unitedstates","23":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115428140665898030","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/328633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=328633"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/328633\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/328634"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=328633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=328633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=328633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}